Factor VIII S373L: Mutation at P1’ Site Confers Thrombin Cleavage Resistance, Causing Mild Haemophilia A

Summary

A novel CRM+ mutation, factor VIII position 373 serine to leucine substitution (FVIII 373-Leu) was identified during a survey of Factor VIII (FVIII) mutations. We have purified the variant protein from the patient's plasma in order to allow further characterisation of the molecule. The CRM+ plasma contained 120% Factor VIII antigen (FVIILAg) and 6% Factor Vili coagulant activity (FVIILC). After purification the mutant FVIII was subjected to thrombin proteolysis, and was thereby activated 5.6-fold compared with 7-fold for wild type molecule. Subsequently, spontaneous inactivation of the mutant was much slower than noted for wild type FVIII. Western blot analysis using monoclonal antibodies demonstrated that thrombin cleavage of FVIII 373-Leu at positions 740 and 1689 were normal but that cleavage at position 372 was completely absent.

Crystallographic coordinates of the active site of thrombin complexed to fibrinopeptide A were used to explore possible mechanistic reasons for the failure of thrombin to cleave the mutant FVIII at position 372. Steric hindrance between the mutant side chain and the side chain of the PI residue was apparent. We conclude that the functional defect of FVIII 373-Leu results from the inability of thrombin to cleave the mutant at position 372-373, and propose that this is due to steric hindrance by the side chain of leucine 373, preventing correct formation of the enzyme substrate complex.

• References

• 1 O’Brien DP, Tuddenham EGD. Purification and characterisation of factor VIII 1,689-Cys: A nonfunctional cofactor occurring in a patient with severe haemophilia A. Blood 1989; 73: 2117-22
• 2 O’Brien DP, Pattinson JK, Tuddenham EGD. Purification and characterisation of factor VIII 372-Cys: A hypofunctional cofactor from a patient with moderately severe haemophilia A. Blood 1990; 75: 1664-72
• 3 Arai M, Inaba H, Higuchi M, Antonarakis SE, Kazazian HH, Fujimaki M, Hoyer LW. Direct characterization of factor VIII in plasma: detection of a mutation altering a thrombin cleavage site (arginine-372-histidine). Proc Natl Acad Sci USA 1989; 86: 4277-81
• 4 Arai M, Higuchi M, Antonarakis SE, Kazazian HH, Phillipps JA, Janco RL, Hoyer LW. Characterization of a thrombin cleavage site mutation (Arg 1689 to Cys) in the factor VIII gene of two unrelated patients with cross-reacting material-positive hemophilia ABlood . 1990: 384-89
• 5 Eaton DL, Vehar GA. Factor VIII structure and proteolytic processing. In: Hemostasis and Thrombosis Coder BS. (ed) Grune & Stratton. Inc.; 1986. (; 8). 47-90
• 6 Eaton DL, Rodriguez H, Vehar GA. Proteolytic processing of human factor VIII. Correlation of specific cleavages by thrombin, factor Xa and activated protein C with activation and inactivation of factor VIII coagulant activity. Biochemistry 1986; 25: 505-12
• 7 Pittman DD, Kaufmann RJ. Proteolytic requirements for thrombin activation of antihemophilic factor (factor VUI). Proc Natl Acad Sci USA 1988; 85: 2429-933
• 8 Acquila M, Caprino D, Pecorara M, Baudo F, Morfini M, Mori PG. Two novel mutations at 373 codon of FVIII gene detected by DGGE. Thromb Haemostas 1993; 69: 392-3
• 9 Bradford M. A Rapid and sensitive method for the quantitation of microgram quantities of protein using the principal of protein dye binding. Anal Biochem 1976; 72: 248-54
• 10 Rotblat F, Tuddenham EGD. Immunological studies of factor VIII coagulant activity (VIII.C). Assays based on a haemophilic and an acquired antibody to FVIIFC. Thromb Res 1981; 21: 43-45
• 11 Rotblat F, Goodall AH, O’Brien DP, Rawlings E, Middleton S, Tuddenham EGD. Monoclonal antibodies to human procoagulant factor VIII. J Lab Clin Med 1983; 101: 736-46
• 12 Rotblat F, O’Brien D, O’Brien F, Goodall AH, Tuddenham EGD. Purification of human factor VIII:C and its characterisation by western blotting using monoclonal antibodies. Biochemistry 1985; 24: 4294-4300
• 13 Martin PD, Robertson W, Turk D, Huber R, Bode W, Edwards BFP. The structure of residues 7-16 of the cc-chain of human fibrinogen bound to bovine thrombin at 2,3-A resolution. J Biol Chem 1992; 267: 7911-20
• 14 Lollar P, Parker CG. pH dependent denaturation of thrombin-activated porcine factor VIII. J Biol Chem 1990; 265: 1688-92
• 15 Lollar P, Parker ET. Structural basis for the decreased procoagulant activity of human factor VIII compared to the porcine homolog. J Biol Chem 1991; 266: 12481-6
• 16 Pittman DD, Millenson M, Marquette K, Baur K, Kaufman RK. A2 domain of human recombinant-derived factor VIII is required for procoagulant activity but not for thrombin cleavage. Blood 1992; 79: 389-97
• 17 Lamphear BJ, Fay PJ. Factor IXa enhances reconstitution of factor Villa from isolated A2 Subunit and A1/A3-C1-C2 dimer. J Biol Chem 1992; 267: 2735-30
• 18 Tiarks C, Ghalili K, Humphreys R, Goodall AH, Tuddenham EGD, Pechet L. Identification of six functional clotting factor VIII : C epitopes by analysis of cross reactive public idiotypes in murine monoclonal VIII : C inhibitors. Thromb Res 1987; 45: 527-37
• 19 Stenflo J. The biochemistry of protein C. In: Bertine RM. (ed) Protein and Related Proteins Churchill Livingstone; Edinburgh: pp 21-54 1988